A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

NCT02912949 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

250

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumours Harboring NRG1 Fusion
NSCLC Harboring NRG1 Fusion
Pancreatic Cancer Harboring NRG1 Fusion
NRG1 Fusion

Interventions

DRUG: zenocutuzumab (MCLA-128)

Sponsor

Partner Therapeutics, Inc.